Friday, April 26, 2019 1:45:55 PM
Certainly, Anavex Drugs Have Been Tested For Prophylaxis
Understandably, many will regard my suggestions of Anavex drugs as anti-aging agents as pure speculation. Way out. Without any supporting evidence.
Personally, I know of no specific evidence of Anavex anti-aging competencies. But I’m certain Anavex researchers have privately done the murine (lab rodent) tests on the topic.
The aging biology of lab rats and mice is probably better known than the aging processes in real humans. The testing of anti-aging outcomes in murines would not be hazy guesswork. Humans live many decades. Lab rats and mice only many months. The progression of aging indications is well-known. Any therapy that slows or delays murine aging can be well-assessed.
People expert in murine research know all of the factors the can prompt or increase rodent aging. Various feeding and nutrition protocols can induce aging (as with we humans). Various genetic lines of mice and rats have accelerated aging. Anavex drugs can be administered to any of these and in less then two year’s assessment time suppression of aging can be accurately detected.
None of this is deep neurology or brain chemistry. Any biology grad student could conduct the research and collect the data. There is an existing body of knowledge on how to run aging tests on murines, particularly with veterinary scientists.
“Yea, but we ain’t rats.”
No we aren’t. But rats don’t have cell mechanism that work differently from humans. Rats and us have DNA, mitochondria, endoplasmic reticula, with virtually identical biochemical pathways. Rats get old; so do we — just at different rates. Things that keep rats younger longer are very likely to have the same outcome in humans.
Anavex people know of this (so much better). They’ve had researchers working on this for some time. Tip of the iceberg information (for those who recall how that phrase first appeared on this message board).
Understandably, many will regard my suggestions of Anavex drugs as anti-aging agents as pure speculation. Way out. Without any supporting evidence.
Personally, I know of no specific evidence of Anavex anti-aging competencies. But I’m certain Anavex researchers have privately done the murine (lab rodent) tests on the topic.
The aging biology of lab rats and mice is probably better known than the aging processes in real humans. The testing of anti-aging outcomes in murines would not be hazy guesswork. Humans live many decades. Lab rats and mice only many months. The progression of aging indications is well-known. Any therapy that slows or delays murine aging can be well-assessed.
People expert in murine research know all of the factors the can prompt or increase rodent aging. Various feeding and nutrition protocols can induce aging (as with we humans). Various genetic lines of mice and rats have accelerated aging. Anavex drugs can be administered to any of these and in less then two year’s assessment time suppression of aging can be accurately detected.
None of this is deep neurology or brain chemistry. Any biology grad student could conduct the research and collect the data. There is an existing body of knowledge on how to run aging tests on murines, particularly with veterinary scientists.
“Yea, but we ain’t rats.”
No we aren’t. But rats don’t have cell mechanism that work differently from humans. Rats and us have DNA, mitochondria, endoplasmic reticula, with virtually identical biochemical pathways. Rats get old; so do we — just at different rates. Things that keep rats younger longer are very likely to have the same outcome in humans.
Anavex people know of this (so much better). They’ve had researchers working on this for some time. Tip of the iceberg information (for those who recall how that phrase first appeared on this message board).
Recent AVXL News
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
- Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm • PR Newswire (US) • 01/09/2026 01:13:00 AM
- Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology • GlobeNewswire Inc. • 01/08/2026 12:30:00 PM
- Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program • GlobeNewswire Inc. • 01/06/2026 12:30:00 PM
- Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion • GlobeNewswire Inc. • 12/18/2025 12:30:00 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 12/12/2025 09:05:00 PM
